DRUG COMBINATIONS
Testing drugs as it happens in the human body is important to recapitulate the dynamics and cause-effects of in vivo tumours. Addressing this, ScreenIn3D has developed a technology that enables shear stress free perfusion to be applied to multiple 3D models without the need for tubing or flow actuation equipment.
Combination therapy is an important approach and demonstrated to improve treatment outcomes in cancer. It targets multiple disease pathways simultaneously, can hinder disease resistance whilst enhancing therapeutic effects. Therapy combination strategies are at the core of personalized treatment approaches, shaping the future of treatment in many medical fields. During lead optimization stages, hundreds of drugs can be tested in combination and the ability to
implement these tests on patent-derived tissue is essential to de-risk drug candidate selection at earlier stages of drug discovery and to facilitate drug repurposing strategies with huge financial implications.
To meet this need, ScreenIn3D has developed a technology capable of performing large drug combination testing directly on very small quantities of tissue-derived samples while maintaining physiological conditions.’
Here, we tested the synergistic effects of two compounds on 3D colorectal cancer models, repeating experiments reported in (Scientific Reports, 2018, 8, 17744) and showing correlation with the literature. The platform offers a unique system to miniaturize drug combination studies using small quantities of cell samples, enabling fast selection of drug combination ‘hits’ for drug discovery.
